![아이메디신 [ iMediSync ]](https://www.imedisync.com/wp-content/uploads/2021/10/imedisync_logo.png){kind=logo}
PROPRIETARY
아이메디신, 하나금융투자와 삼성증권 KOSDAQ IPO 선정
iMediSync hires Hana Financial Investment, Samsung Securities for KOSDAQ IPO in 2022 – exec28 SEP 2020
iMediSync, a South Korean AI (artificial intelligence) healthcare company, has mandated Hana Financial Investment and Samsung Securities as lead managers for its KOSDAQ listing, General Manager at Management Team Lee Ji-won said.
The Seoul-headquartered company had shortlisted advisors for its initial public offering (IPO), and was considering appointing two lead managers, CEO Kang Seung-wan told this news service last week.
The healthtech rm aims to make its market debut on KOSDAQ by 2Q22 and raise about KRW130bn (USD 110m) via listing, Kang noted.
iMediSync also plans to raise around KRW 15bn (USD 12m) in a pre-IPO round in 1H21 to beef up its digital mental healthcare platform used for early diagnosis of cognitive disorders, he noted.
In April this year the company raised KRW 5bn in its Series B round from Korea Development Bank and A Ventures, as announced.
iMediSync’s main platform, iSyncBrain, an AI-powered brainwave analysis engine structured with a standardized normative database specific to age and gender, detects biomarkers in early-stage mild cognitive impairment, according to its website.
The platform analyzes an individual’s brainwaves and identifies in 10 minutes with quantitative electroencephalography (QEEG) early signals of cognitive impairment, which can further lead to other illnesses such as dementia, Parkinson’s disease, and addiction.
The South Korean Ministry of Food and Drug Safety approved iSyncBrain as a medical device earlier this year and the company plans to commercialize the product starting next year, Kang noted.
iMediSync announced earlier this month that it has been selected by the South Korean Ministry of SMEs and Startups to receive government aid to develop its non-face-to-face dementia prevention platform and wearable medical device.
Founded in 2013 by Kang, iMedisync currently has 38 employees, the CEO noted.
